Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 2Phase 2 1Phase 1 1

Status

Recruiting 11Active not recruiting 7

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 2Breast 2Gynecologic 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2mCRPC 1Ovarian Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1

Interventions

Specimen Handling 218Magnetic Resonance Spectroscopy 194pembrolizumab 185Carboplatin 160Biopsy 129Cisplatin 128Nivolumab 119Paclitaxel 107Cyclophosphamide 104Radiotherapy 99Gemcitabine 96Dexamethasone 86durvalumab 83atezolizumab 70Rituximab 66Radiation 64Lenalidomide 64Doxorubicin 63Pemetrexed 61Bevacizumab 58Etoposide 56Docetaxel 56olaparib 50Ipilimumab 49Fluorouracil 48Taxes 47Prednisone 47Oxaliplatin 46Vincristine 45Cytarabine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Active not recruiting × talazoparib × 90 days × Clear all
NCT04334941 2026-06-05

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

National Cancer Institute (NCI)

Phase 2 Active not recruiting
103 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT04846478 2026-05-12

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
35 enrolled
Genitourinary

Prostatic Neoplasms

NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting
1,054 enrolled 21 charts 1 FDA

mCRPC

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Pfizer

Phase 3 Active not recruiting
68 enrolled
Gynecologic

Ovarian Neoplasms

NCT03964532 2026-04-09

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Georgetown University

Phase 1/2 Active not recruiting
24 enrolled
Breast

Breast Neoplasms

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Pfizer

Phase 3 Active not recruiting
599 enrolled
Genitourinary

Prostatic Neoplasms

NCT04039230 2026-03-16

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Massachusetts General Hospital

Phase 1/2 Active not recruiting
75 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡